Amgen (AMGN) Equity Average (2009 - 2026)

Amgen's Equity Average history runs 18 years deep, the most recent figure standing at $8.9 billion for Q1 2026.

• In Q1 2026, Equity Average rose 47.7% year-over-year to $8.9 billion; the TTM figure through Mar 2026 stood at $8.9 billion (up 47.7% YoY), while the FY2025 annual figure was $7.3 billion, up 20.03% from the prior year.
• Equity Average was $8.9 billion for Q1 2026 at Amgen, down from $9.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $9.1 billion in Q4 2025 to a low of $1.7 billion in Q2 2022.
• Historically, Equity Average has averaged $5.9 billion across 5 years, with a median of $6.1 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Equity Average tumbled 81.03% in 2022, then jumped 263.69% in 2023.
• A 5-year view of Equity Average shows it stood at $3.7 billion in 2022, then jumped by 89.88% to $6.9 billion in 2023, then fell by 3.49% to $6.7 billion in 2024, then jumped by 36.35% to $9.1 billion in 2025, then declined by 2.35% to $8.9 billion in 2026.
• The last three Equity Average figures came in at $8.9 billion (Q1 2026), $9.1 billion (Q4 2025), and $8.5 billion (Q3 2025), per Business Quant data.